Literature DB >> 22999134

Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7.

David M Eddy1, William Hollingworth, J Jaime Caro, Joel Tsevat, Kathryn M McDonald, John B Wong.   

Abstract

Trust and confidence are critical to the success of health care models. There are two main methods for achieving this: transparency (people can see how the model is built) and validation (how well the model reproduces reality). This report describes recommendations for achieving transparency and validation developed by a taskforce appointed by the International Society for Pharmacoeconomics and Outcomes Research and the Society for Medical Decision Making. Recommendations were developed iteratively by the authors. A nontechnical description--including model type, intended applications, funding sources, structure, intended uses, inputs, outputs, other components that determine function, and their relationships, data sources, validation methods, results, and limitations--should be made available to anyone. Technical documentation, written in sufficient detail to enable a reader with necessary expertise to evaluate the model and potentially reproduce it, should be made available openly or under agreements that protect intellectual property, at the discretion of the modelers. Validation involves face validity (wherein experts evaluate model structure, data sources, assumptions, and results), verification or internal validity (check accuracy of coding), cross validity (comparison of results with other models analyzing the same problem), external validity (comparing model results with real-world results), and predictive validity (comparing model results with prospectively observed events). The last two are the strongest form of validation. Each section of this article contains a number of recommendations that were iterated among the authors, as well as among the wider modeling taskforce, jointly set up by the International Society for Pharmacoeconomics and Outcomes Research and the Society for Medical Decision Making.
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22999134     DOI: 10.1016/j.jval.2012.04.012

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  125 in total

Review 1.  Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches.

Authors:  Dyfrig Hughes; Joanna Charles; Dalia Dawoud; Rhiannon Tudor Edwards; Emily Holmes; Carys Jones; Paul Parham; Catrin Plumpton; Colin Ridyard; Huw Lloyd-Williams; Eifiona Wood; Seow Tien Yeo
Journal:  Pharmacoeconomics       Date:  2016-05       Impact factor: 4.981

2.  Accounting for biases when linking empirical studies and simulation models.

Authors:  Jeremy D Goldhaber-Fiebert
Journal:  Med Decis Making       Date:  2012 May-Jun       Impact factor: 2.583

Review 3.  Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review.

Authors:  Xiao Zang; Emanuel Krebs; Linwei Wang; Brandon D L Marshall; Reuben Granich; Bruce R Schackman; Julio S G Montaner; Bohdan Nosyk
Journal:  Pharmacoeconomics       Date:  2019-10       Impact factor: 4.981

4.  Optimal healthcare decision making under multiple mathematical models: application in prostate cancer screening.

Authors:  Dimitris Bertsimas; John Silberholz; Thomas Trikalinos
Journal:  Health Care Manag Sci       Date:  2016-09-17

5.  Decision-analytic models: current methodological challenges.

Authors:  J Jaime Caro; Jörgen Möller
Journal:  Pharmacoeconomics       Date:  2014-10       Impact factor: 4.981

Review 6.  Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview.

Authors:  Erik J Dasbach; Elamin H Elbasha
Journal:  Pharmacoeconomics       Date:  2017-07       Impact factor: 4.981

7.  Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations.

Authors:  Luis Hernandez; Malinda O'Donnell; Maarten Postma
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

Review 8.  Cost-Effectiveness of Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy: a Critical Review.

Authors:  Nataniel H Lester-Coll; David J Sher
Journal:  Curr Oncol Rep       Date:  2017-06       Impact factor: 5.075

9.  Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada.

Authors:  William Herring; Isobel Pearson; Molly Purser; Hamid Reza Nakhaipour; Amin Haiderali; Sorrel Wolowacz; Kavisha Jayasundara
Journal:  Pharmacoeconomics       Date:  2016-01       Impact factor: 4.981

10.  Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events.

Authors:  Thomas S G Sehested; Jenny Bjerre; Seul Ku; Andrew Chang; Alison Jahansouz; Douglas K Owens; Mark A Hlatky; Jeremy D Goldhaber-Fiebert
Journal:  JAMA Cardiol       Date:  2019-02-01       Impact factor: 14.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.